- Home
- LTRN vs OSTX Comparison
LTRN vs OSTX Comparison
Compare LTRN & OSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- OSTX
- Stock Information
- Founded
- LTRN 2013
- OSTX 2018
- Country
- LTRN United States
- OSTX United States
- Employees
- LTRN N/A
- OSTX N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- OSTX
- Sector
- LTRN Health Care
- OSTX
- Exchange
- LTRN Nasdaq
- OSTX NYSE
- Market Cap
- LTRN 36.0M
- OSTX 43.0M
- IPO Year
- LTRN 2020
- OSTX 2024
- Fundamental
- Price
- LTRN $4.02
- OSTX $1.62
- Analyst Decision
- LTRN Strong Buy
- OSTX Strong Buy
- Analyst Count
- LTRN 1
- OSTX 3
- Target Price
- LTRN $25.00
- OSTX $18.00
- AVG Volume (30 Days)
- LTRN 312.5K
- OSTX 765.9K
- Earning Date
- LTRN 08-07-2025
- OSTX 08-14-2025
- Dividend Yield
- LTRN N/A
- OSTX N/A
- EPS Growth
- LTRN N/A
- OSTX N/A
- EPS
- LTRN N/A
- OSTX N/A
- Revenue
- LTRN N/A
- OSTX N/A
- Revenue This Year
- LTRN N/A
- OSTX N/A
- Revenue Next Year
- LTRN N/A
- OSTX N/A
- P/E Ratio
- LTRN N/A
- OSTX N/A
- Revenue Growth
- LTRN N/A
- OSTX N/A
- 52 Week Low
- LTRN $2.55
- OSTX $1.12
- 52 Week High
- LTRN $6.12
- OSTX $7.00
- Technical
- Relative Strength Index (RSI)
- LTRN 67.20
- OSTX N/A
- Support Level
- LTRN $3.15
- OSTX N/A
- Resistance Level
- LTRN $4.43
- OSTX N/A
- Average True Range (ATR)
- LTRN 0.38
- OSTX 0.00
- MACD
- LTRN 0.11
- OSTX 0.00
- Stochastic Oscillator
- LTRN 80.91
- OSTX 0.00
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.